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Abstract
Despite intensive eradication therapy, some CF patients with early Pseudomonas aeruginosa infection rapidly develop a chronic infection.
To elucidate factors associated with this persistence, bacterial characteristics of early P. aeruginosa isolates were analysed that were either
eradicated rapidly or persisted despite multiple antimicrobial treatments. Eighty-six early infection episodes were studied. First P. aerugin-
osa isolates from patients with eradication (36) or persistent infection (16) were included; isolates from patients with intermittent infec-
tion (34) were omitted from the study. Virulence assays, antimicrobial resistance, cytotoxicity and mutation frequencies were analysed in
vitro. P. aeruginosa was genotyped by SNP-array. Transcriptomic proﬁles of two eradicated and two persistent strains were compared.
Nineteen per cent of patients developed persistent infection; 42% achieved eradication. Secretion of virulence factors and mutation
frequencies were highly variable among both eradicated and persistent isolates and were not different between the groups. Cytotoxicity
was present in 57% of eradicated vs. 100% of persistent isolates (p <0.01). None of the isolates were resistant to antibiotics. The isolates
were genotypically highly diverse. Multivariate analysis showed that in vitro determined bacterial characteristics could not predict persis-
tence after ﬁrst P. aeruginosa infection. Preliminary transcriptomic data showed increased expression of some genes related to a metabolic
pathway. The early onset of chronic infection was not associated with (in vitro determined) bacterial characteristics only. Although the
persistent isolates were more often cytotoxic, for the individual patient it was not possible to predict the risk of persistence based on
bacterial characteristics. Unknown factors such as host-pathogen and pathogen-pathogen interactions should be further explored.
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Introduction
Patients with cystic ﬁbrosis (CF) are at risk for chronic pul-
monary Pseudomonas aeruginosa infection because of abnormal
mucociliary clearance, high pulmonary salt concentrations,
and altered bacterial epithelial adherence and internalization
[1,2]. Consequently, early infection is intensively treated with
combined antimicrobial therapy, leading to, albeit temporal,
eradication of P. aeruginosa in the majority of patients. How-
ever, amongst 10–40% of patients eradication fails, leading to
chronic infection shortly after the ﬁrst positive culture [3,4].
Identiﬁcation of those patients at risk for progression to
chronic P. aeruginosa infection is difﬁcult. Host factors that
cause predisposition to chronic P. aeruginosa infection are
female gender, number of dF508 alleles, decreased lung function
and absence of Staphylococcus aureus in sputum cultures [5].
Generally, initial P. aeruginosa isolates express multifacto-
rial virulence [2]. Synthesis of a number of virulence factors
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is controlled by the quorum sensing system. This system is
regulated by two transcriptional activators, lasR or rhlR,
which are activated by its autoinducer molecules N-3-oxodo-
decanoyl homoserine lactone (C12-HSL) and N-butyryl-L-
homoserine lactone (C4-HSL) [6]. Progression to chronic
infection is characterized by genetic diversiﬁcation through
numerous mutations, leading to a gradual loss of virulence,
production of bioﬁlm and change in metabolic proﬁles, lead-
ing to various phenotypes [7,8]. Pseudomonas aeruginosa
adaptation is initiated early in the infection course and is
promoted by the CF airway environment, being inﬂammatory
with anaerobic sputum in the conductive airways [9].
Uncertainty exists over whether rapid adaptation leading
to loss-of-function mutations causes predisposition to persis-
tence of infection. Enhanced virulence may also be associated
with persistent infection. Type III secretion enzymes induce
direct epithelial and neutrophil cytotoxicity [10,11]. In non-
CF patients suffering from P. aeruginosa ventilator-associated
pneumonia, high type III secretion determined risk for persis-
tent infection despite antimicrobial therapy [12]. Additionally,
bioﬁlm production is a strong predictor of chronic infection.
In a recently published follow-up study, eradication of ﬁrst
P. aeruginosa isolates was higher for non-mucoid isolates
(77%) than for mucoid isolates (50%) [13]. However, mucoid
isolates are not frequently detected as initial isolates and
might possibly be considered as already adapted to the CF
airways, despite being the ﬁrst isolate to be discovered.
Cystic ﬁbrosis-speciﬁc highly transmissible P. aeruginosa
clones are able to chronically infect P. aeruginosa-negative
patients as well as replace other P. aeruginosa isolates in the CF
lungs. The success of these clones in promoting persistent
infection is apparently related to either high virulence or
involvement of an optimized metabolic proﬁle in the absence
of high virulence [14,15]. Murine P. aeruginosa pulmonary infec-
tion models are contradictory with respect to the capacity of
non-virulent isolates to persist after initial infection [16–18].
To elucidate bacterial mechanisms that may promote per-
sistence in the very early phase, we explored in vitro charac-
teristics of initial infecting P. aeruginosa isolates. Phenotype,
genotype, cytotoxicity and transcriptomic proﬁles were eval-
uated in isolates derived from CF patients with evident erad-
ication and from CF patients with evident persistent
infection after initial infection.
Methods
Patients, samples and microbiology
The CF centres of the University Medical Centre Utrecht,
the Netherlands, and of the Rigshospitalet Copenhagen, Den-
mark, participated in this study. At each visit patients pro-
vided a sputum sample; cough swabs or nasolaryngeal
suction specimens were obtained if patients were unable to
produce sputum. Within the Dutch CF centre, patients were
fully segregated; within the Danish CF centre segregation
was based on microbial cultures. Patient data were extracted
from CF databases.
Pseudomonas aeruginosa was identiﬁed by standard microbi-
ological methods on solid media, by a positive oxidase reac-
tion and by C-390 (9-chloro-9-(4-diethylaminophenyl)-
10-phenylacridan) resistance (Rosco, Taastrup, Denmark).
Susceptibility testing for aminoglycosides, b-lactams, poly-
myxins and ﬂuoroquinolones was performed by disk diffusion
using Neo-Sensitabs (Rosco). Results were interpreted
according to CLSI breakpoints. P. aeruginosa isolates were
stored at )80C till handling. The initial infecting and consec-
utive isolates were prospectively collected between 2004
and 2008.
Infection status and included isolates
A P. aeruginosa isolate was considered ‘initial’ when it was
the ﬁrst P. aeruginosa ever detected in a CF patient (‘never
P. aeruginosa’) or the ﬁrst isolate detected after at least
1 year of P. aeruginosa-free cultures without (maintenance)
anti-Pseudomonas therapy (‘P. aeruginosa free’). The eradica-
tion therapy differed between the two centres, being mainly
3 weeks oral ciproﬂoxacin plus 3 months inhaled colistin for
Danish patients or 3 weeks oral ciproﬂoxacin plus 2 months
high-dose inhaled tobramycin for Dutch patients. Patients
were cultured at least 3-monthly and immediately after erad-
ication therapy. Infection episodes were categorized as ‘erad-
icated’ (with no P. aeruginosa returning in cultures within
1 year after one eradication treatment cycle) or as ‘persis-
tent’ (no eradication achieved after the ﬁrst and consecutive
eradication therapies; >50% of cultures P. aeruginosa positive;
all the isolates shared an identical genotype). To study iso-
lates in clearly distinct groups, episodes that could not be
attributed to one of these categories (intermittent infection)
were not included in the study. Phenotypically different iso-
lates from one patient were both included in the analysis.
Characterization of isolates
The initial and consecutive P. aeruginosa isolates were geno-
typed (SNP-array of core and accessory genome) to establish
persistence of infection. All initial isolates were characterized
by phenotyping (swimming (ﬂagella) and twitching (pili) motil-
ity, protease-, pyocyanin- and C4/C12-HSL concentration),
mutation frequency count and IB3-1 CF bronchial cell-line
cytotoxicity. Further information can be found in the Sup-
porting Information.
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Microarray sample procession and data analysis
Transcriptomic proﬁles of two eradicated and two persistent
isolates were assessed with Affymetrix P. aeruginosa gene chip.
These isolates were derived from patients with an identical
CFTR genotype (homozygous dF508), antimicrobial eradica-
tion therapy (ciproﬂoxacin and tobramycin) and age (5.67–
6.81 years old). Triplicate experiments were performed for
each strain, as further explained in the Supporting Information.
Statistical analysis
Phenotype results were categorized according to the 15th,
50th and 85th percentiles. Differences in proportions were
estimated by the chi-square test or Fisher’s exact test. Con-
tinuous data were analysed with the Student’s t-test or
Mann–Whitney U-test, depending on normality. Values are
expressed as means ± standard error of the mean (SEM).
Univariate- and multivariate analyses were performed to esti-
mate odds ratios (OR) for bacterial- and host-related factors.
Factors that showed a p-value <0.15 were included in the
multivariate analysis. Measures of association were deter-
mined by Pearson or Spearman correlation coefﬁcients. Cal-
culations were performed with SPSS version 15.0 (Chicago,
Illinois, USA). To compare the transcriptomic differences
between the eradicated and persistent isolates, a loggit-t test
comparing the expression data of the two groups was car-
ried out. Further details on microarray analysis can be found
in the Supporting Information.
Results
Patients and treatments
Forty-six Dutch and 40 Danish CF patients were included.
The mean age of P. aeruginosa acquisition was 7.7 years
(range 0.8–24.1) and was not different between the two CF
centres. Female patients were over-represented (60% female
vs. 40% male), but were on average not younger when
acquiring initial P. aeruginosa infection. Sixteen (19%) patients
progressed to persistent infection shortly after initial P. aeru-
ginosa isolation. Thirty-six (42%) patients achieved long-term
eradication. Fig. 1 shows the participant ﬂow diagram. Two
patients with persistent infection with the Dutch highly pre-
valent clone were excluded from further comparative analy-
sis (see below); thus isolates from 50 patients were
analysed.
Patients with persistent infection were older than patients
with eradication. Previously treated P. aeruginosa infection
episodes (mean 3.4 years before included episode) did not
more frequently result in persistent infection. The type of
eradication therapy and the CF centre were not determina-
tive for eradication success. Patients with homozygous dF508
mutation did not more often progress to persistent infection
and were not younger when progressing to persistent infec-
tion. Table 1 shows baseline data of patients with eradication
and persistent infection.
Genotyping
Pseudomonas aeruginosa genotypes were highly diverse in
both groups. Seven genotype pairs were observed; the acces-
sory genome of the genotype pairs was distinct except for
two genotypes, one type found in both the eradicated and
the persistent group and one type found only in the eradi-
cated group. The relatedness of bacteria (based on 16 binary
SNP codes from the core genome, ﬂagellin and exoenzyme S/
U genes; calculated by eBurst algorithm) is shown in Fig. S1.
Two patients with persistent infections carried the Dutch CF
highly prevalent genotype A418 [19]. These isolates
were omitted from further comparative analysis because of
FIG. 1. Number of participants and ﬂow
diagram. NL, the Netherlands; DK,
Denmark. *P. aeruginosa free after ﬁrst
treatment cycle for >1 year. P. aeruginosa
intermittently isolated in the year after
initial infection; eradication after >1
treatment cycle or eradication after ﬁrst
treatment cycle and re-isolation in the
year after initial infection. #No eradication
despite several treatment cycles and
subsequent genotypes identical.
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probable distinct transmitting and infecting potential com-
pared with non-clonal, often environmental isolates.
Fifty-two per cent of isolates were exoS positive, and 10%
exoU positive. The exoS gene was not more often encoun-
tered in persistent isolates (OR, 1.12; 95% CI, 0.33–3.84;
p 0.860). There were no differences in distribution of alleles
of the core and accessory genome and in distribution of one
or more genomic islands between the eradicated and persis-
tent isolates.
Phenotyping
Virulence factors. Two of the eradicated isolates were mucoid.
All bacteria were susceptible to investigated antibiotics. Pili,
ﬂagella, protease, pyocyanin, C4-HSL and C12-HSL expression
were highly variable in both groups and were not signiﬁcantly
different between the groups. Phenotype ﬁgures and distribu-
tions are shown in Table 2 and Fig. 2(a). The persistent iso-
lates showed more often motility and protease values ‡p50;
32% (eradicated) vs. 14% (persistent) had one or more viru-
lence factors <p15. Twitching and swimming motility were
correlated (Spearman r 0.298; p 0.033); only twitching was
correlated with protease (Spearman r 0.403; p 0.003). Pyocya-
nin secretion was not related to any of the other virulence fac-
tors. C4-HSL was correlated with protease (Spearman r 0.309;
p 0.026) but not with the other virulence factors and cyto-
toxicity. C12-HSL was not related to any of the virulence factors.




(n = 14) OR (95% CI) p-value
Pseudomonas aeruginosa acquisition age 5.7 ± 0.6 10.6 ± 1.5 1.3 (1.1–1.5) 0.006
Previous single isolation of P. aeruginosa 4 (11) 4 (29) 3.3 (0.7–15.6) 0.133
Female gender 23 (63.9) 6 (40) 0.3 (0.1–1.2) 0.097
Staphylococcus aureus in previous year 24 (71) 9 (64) 0.8 (0.2–2.8) 0.669
Haemophilus inﬂuenza in previous year 20 (57) 7 (50) 0.8 (0.2–2.6) 0.650
CF Centre Utrecht/CF Centre Copenhagen 17 (37)/19 (48) 8 (17)/6 (15) 0.7 (0.2–2.3) 0.530
Treatment
Ciproﬂoxacin po/inh. colistin 17 (47) 8 (57) 0.450
Ciproﬂoxacin po/inh. tobramycin 9 (25) 4 (29)
Monotherapy ciproﬂoxacin po, inh. colistin or tobramycin. 5 (14) 0 (0)
Tobramycin/ceftazidim or piperacillin/tazobactam i.v. 1 (3) 2 (14)
No therapy 4 (11) 0 (0)
CFTR mutations
dF508/dF508 21 (58) 10 (71) 1.9 (0.5–7.2) 0.342
dF508/other 12 (33) 4 (29)
Other/other 3 (8) 0 (0)
Sputum producers 7 (19) 4 (29) 1.7(0.4–6.9) 0.487
Data are indicated as means ± SEM and n (%)




(14) OR (95% CI) p-value
Swimming motility (range 0–64 mm) 37.2 ± 2.4 43.56 ± 3.0 1.04 (0.98–1.10) 0.159
N < p15 (29) 7 (19) 0 (0) 0.168
N ‡ p50 (41) 20 (54) 8 (62) 0.843
N > p85 (50) 3 (8) 5 (39) 0.021
Twitching motility (range 0–41 mm) 25.4 ± 2.3 29.8 ± 3.4 1.03 (0.98–1.08) 0.308
N < p15 (2) 7 (19) 1 (7) 0.407
N ‡ p50 (31) 17 (46) 10 (71) 0.104
N > p85 (38) 5 (14) 4 (29) 0.236
Protease (range 0–29 mm) 23.8 ± 1.0 26.0 ± 0.8 1.14 (0.93–1.40) 0.024
N < p15 (21) 7 (19) 1 (7) 0.419
N ‡ p50 (26) 16 (43) 12 (79) 0.024
N > p85 (28) 10 (27) 3(21) 0.733
Pyocyanin (range 0.10–24 mg/L) 8.5 ± 1.1 7.5 ± 1.5 0.97 (0.88–1.08) 0.622
N < p15 (0.42) 4 (11) 3 (21) 0.376
N ‡ p50 (7.50) 19 (51) 7(50) 0.931
N > p85 (15) 6 (16) 1(7) 0.657
One or more virulence factors (motility, protease, pyocyanin) ‡p50 30 (81) 14 (100) 0.169
One or more virulence factors (motility, protease) ‡p50 26 (70) 14 (100) 0.023
C4-HSL (range 0–15.17 lM) 7.28 ± 0.63 8.04 ± 0.76 1.06 (0.89–1.27) 0.496
C12-HSL (range 0–1156 nM) 188.74 ± 23.56 301.57 ± 340.62 1.00 (0.99–1.01) 0.128










Hypermutation (>20-fold) 3 (8.6) 0 (0) 0.545
Cytotoxicity (% lysis) 17.8 ± 4.4 28.8 ± 8.3 1.01 (0.99–1.03) 0.226
Data are indicated as mean ± SE or n (%), unless otherwise stated.
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Mutation frequencies. Hypermutation (>20-fold mutation fre-
quency) was observed in 9% of the eradicated and 0% of
the persistent isolates. A greater than ﬁve-fold increase in
mutation frequency was observed in 16% of isolates. Iso-
lates with a >20-fold mutation rate showed decreased
swimming and twitching capacities (p 0.022 and 0.002) and
lower protease secretion (p 0.047); pyocyanin secretion
was not signiﬁcantly decreased. A more than ﬁve-fold
mutation frequency increase was associated with a
decrease in cytotoxicity (22.9 ± 4.79% vs. 8.21 ± 1.92%,
p 0.006).
Cytotoxicity IB3-1 CF bronchial cell line. Most isolates displayed
moderate or limited cytotoxicity. Absence of cytotoxicity,
deﬁned as <5% lysis, was observed among 31% of isolates
(43% eradicated and 0% persistent; p 0.002). Cytotoxicity ﬁg-
ures can be found in Table 2 and Fig. 2(b). Cytotoxicity was
associated with twitching motility (Spearman r 0.378;
p 0.006) but not with the other virulence factors, conﬁrming
the requirement of pili-mediated bacterial-epithelial contact.
Enter multivariate modelling of phenotypic ﬁgures revealed
no signiﬁcant bacterial characteristics associated with persis-
tence. Odds ratios with conﬁdence intervals and p-values are
shown in Table 2.
Transcriptomic proﬁles
Assessment of other factors important for the early estab-
lishment of persistent P. aeruginosa infection was performed
by transcriptome analysis.
Seventeen genes (Table 3) were differently expressed
between the two eradicated and two persistent isolates.
Seven genes showed increased expression in the persistent
isolates compared with the eradicated isolates. Four of these
genes (dctA, PA5167, PA5168 and PA5169) belong to the C4-
dicarboxylate transport system.
Discussion
This is the ﬁrst study that describes characteristics of initial
P. aeruginosa isolates that were either eradicated or leading
to persistent infection in patients with CF. It is important to
gain more understanding of the initial infection process to
improve treatment of initial P. aeruginosa acquisition in order
FIG. 2. (a) Virulence factor assay results
with medians. (b) Cytotoxicity (% lysis
with medians) on IB3-1 cell layer (dotted
line represents 5% cut off) (• eradicated
isolates and persistent isolates).
CMI Tramper-Stranders et al. P. aeruginosa eradication and persistence in CF 571
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 567–574
to subsequently prevent chronic P. aeruginosa pulmonary
infection.
While chronic infection isolates are generally character-
ized by bacterial adaptation and attenuation of virulence, the
results of this study show that the very early onset of persis-
tent infection could not be predicted by virulence as mea-
sured in vitro.
Patient data
The only patient factor associated with persistence was age;
treatment or previous isolation was not associated. Older
patients might have more pulmonary damage from previous
infections with other microorganisms, facilitating epithelial
attachment of P. aeruginosa. Sinus colonization with P. aerugin-
osa might lead to subsequent lower airway infection [20].
Additionally, co-colonization with other microbial organisms,
which might occur more often in older patients, is signiﬁcant
for up- and/or downregulation of important virulence genes
[21]. Co-colonization with S. aureus and H. inﬂuenzae did not
inﬂuence persistence rate in this study; however, many
microorganisms that are not easily cultured can play an
important role in the infection dynamics. Viral infections and
even oral microﬂora lead to increased P. aeruginosa epithelial
adherence and renewal of virulence [22]. It can be debated
whether the initial isolates actually resided for only a limited
period within the CF airways. Because of the time span,
albeit small, between routinely performed respiratory cul-
tures and sampling technique errors, it is impossible to esti-
mate the exact colonization time. Therefore, we categorized
infection episodes only as eradicated when there were
enough follow-up cultures for a period of at least 1 year.
Additionally, the differentiation between P. aeruginosa coloni-
zation and infection is gradual and uncertain. The majority of
patients do not have respiratory symptoms when P. aerugin-
osa is detected for the ﬁrst time while airway inﬂammation is
present [13,23].
Phenotyping, genotyping and transcriptomics
Our results show a large variability in bacterial characteris-
tics between isolates. There is a trend towards a higher viru-
lence and cytotoxicity, and a lower hypermutation frequency
in persistent isolates. But, prediction for the individual
patient to progress to persistent infection remains difﬁcult.
Other non-investigated virulence factors such as phospholi-
pase C and exotoxins might be involved as well. Interestingly,
eradicated isolates tended to be more often hypermutators
compared with the persistent isolates. This phenomenon
could be illustrated with the mouse model study of Monta-
nari et al. In this model, hypermutable isolates were less efﬁ-
cient in establishing lung infection compared with wild-type
isolates; their transmissibility seemed to be reduced [24].
The percentage of cytotoxicity (69%) in our study group
corresponds to the data of Jain et al. [25], showing around
50% of early CF P. aeruginosa isolates expressing type III
secreting proteins, which is related to cytotoxicity. Increasing
the co-incubation time and adding of EGTA, a calcium chela-
tor, did not lead to major changes in cytotoxicity. El Solh
et al. [12] investigated the cytotoxicity of P. aeruginosa from
patients with ventilator-associated pneumonia and observed
a higher neutrophil cytotoxicity for persistent isolates.
Although the cytotoxicity was higher, there was a large vari-
ability among isolates. The variance was not shown and the
odds ratio was close to one. In a subset of 18 isolates from
our study, human neutrophil cytotoxicity was assessed and
this correlated with IB3-1 cytotoxicity (Pearson r 0.700;
p 0.002; data not shown). In an injured lung, CF host fea-
tures are probably more important in the infection process
than bacterial characteristics, unlike in non-CF patients.
TABLE 3. Differentially expressed genes comparing persistent isolates and eradicated isolates
p-value Fold change Product name Functional classes
Upregulated in persistence group
dctA 0.003 3.59 C4-dicarboxylate transport protein Transport of small molecules
PA1711 0.030 2.39 ExsE Hypothetical, unclassiﬁed, unknown, transcriptional
regulators; protein secretion/export apparatus
PA2252 0.046 2.48 Probable AGCS sodium/alanine/glycine symporter Transport of small molecules
PA5167 0.010 2.74 Probable c4-dicarboxylate-binding protein Membrane proteins; transport of small molecules
PA5168 0.007 2.29 Probable dicarboxylate transporter Membrane proteins; transport of small molecules
PA5169 0.012 2.12 Probable C4-dicarboxylate transporter Membrane proteins; transport of small molecules
tRNA_Phe 0.030 2.71
Downregulated in persistence group
PA0612 0.011 )4.06 Repressor, PtrB Transcriptional regulators
PA0613 0.024 )3.61 Hypothetical protein Hypothetical, unclassiﬁed, unknown
PA0633 0.018 )3.44 Hypothetical protein Related to phage, transposon or plasmid
PA0635 0.035 )2.48 Hypothetical protein Related to phage, transposon or plasmid
PA0636 0.030 )2.48 Hypothetical protein Related to phage, transposon or plasmid
PA0637 0.023 )2.42 Conserved hypothetical protein Related to phage, transposon or plasmid
PA0638 0.027 )2.24 Probable bacteriophage protein Related to phage, transposon or plasmid
PA0639 0.017 )2.20 Conserved hypothetical protein Related to phage, transposon or plasmid
PA1096 0.042 )2.09 Hypothetical protein Hypothetical, unclassiﬁed, unknown
tRNA_Arg 0.022 )2.08
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Our in vitro experiments do not necessarily reﬂect the
in vivo situation in the CF airways but rather the bacterial
ability to display a set of chosen factors in in vitro selected
artiﬁcial conditions. The persistent isolates could show a
different virulence pattern in vivo, or differ in other yet
unknown factors. Probably the host–pathogen interaction,
leading to up- or downregulation of virulence components,
is determinative for persistence of infection. This might be
illustrated by the fact that a few patients shared identical
bacterial SNP genotypes. These genotypes were eradicated
in some patients and persistent in the others, indicating that
the genomic background of a certain strain is not always
decisive regarding whether it will persist in the CF lung.
However, there are some other pathways that might be
essential in this process. Transcriptomic analysis showed
seven genes with increased expression in the persistent
isolates compared with the eradicated isolates. Four (dctA,
PA5167-69) of them belong to the C4-dicarboxylate trans-
port (dct) system. The metabolism of C4-dicarboxylates
requires a bacterial uptake system. In Escherichia coli, DctA
as a symporter is the major carrier in aerobic growth [26].
DctA mutants show very poor growth on C4-dicarboxylates.
In Pseudomonas chlororaphis O6, DctA is also required for
C4-dicarboxylate utulization and effective root colonization
[27]. PA5167-69 are homologous to dctPQM, a transporter
with high afﬁnity to C4-dicarboxylates [28]. In P. aeruginosa,
there are four homologous operons of dctPQM including
PA5167-69 and their function has not been studied. In
conclusion, it is likely that the dctA and dctPQM genes are
responsible for or partly involved in C4-dicarboxylates
uptake in certain conditions. Upregulation of those genes in
the persistent isolates indicates that the C4-dicarboxylates
transport might be important for early persisting infection of
P. aeruginosa. It could also give hints on carbon sources that
P. aeruginosa depends on in early CF infection. However,
expression of dct genes has to be examined in a bigger
sample size to prove their importance.
Conclusion
Only age was related to development of chronic infection
after initial P. aeruginosa infection. Although persistent iso-
lates were more often cytotoxic, it is difﬁcult to predict
the chance of persistence based only on in vitro bacterial
characteristics because of a large variety. Unknown factors
such as host–pathogen and pathogen–pathogen interactions
should be further explored. Intensive antibiotic eradication
therapy for all patients with ﬁrst P. aeruginosa infection
remains advised. Investigations should be carried out
regarding whether patients will beneﬁt from adjuvant ther-
apy targeted at virulence to prevent persistent P. aeruginosa
infection.
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